Headquartered in Stockholm, Sweden, Immedica is a pharmaceutical company focused on the commericalization of medicines for rare and specialty diseases.
Our services cover marketing and sales, compliance, pharmacovigilance, compliance, quality assurance, regulatory and medical affairs and market access. Serving patients in more than 50 countries, we are fully dedicated to helping those living with diseases which have a large unmet medical need. Our therapeutic areas are within genetic & metabolic diseases, hematology & oncology and specialty care.
Immedica was founded in 2018. By that time we were 7 employees and had a turnover of SEK 85 M. Now we are more than 140 employees with a turnover above SEK 1 billion. Our two main owners are the investment firms Impilo and KKR.
